These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 14679009

  • 1. Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.
    Edinger AL, Linardic CM, Chiang GG, Thompson CB, Abraham RT.
    Cancer Res; 2003 Dec 01; 63(23):8451-60. PubMed ID: 14679009
    [Abstract] [Full Text] [Related]

  • 2. Mammalian target of rapamycin promotes vincristine resistance through multiple mechanisms independent of maintained glycolytic rate.
    Vanderweele DJ, Rudin CM.
    Mol Cancer Res; 2005 Nov 01; 3(11):635-44. PubMed ID: 16317089
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y, Zhao Q, Ma S, Yang F, Gong Y, Ke C.
    IUBMB Life; 2007 Nov 01; 59(11):717-21. PubMed ID: 17968710
    [Abstract] [Full Text] [Related]

  • 4. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 5. Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the Bax : Bcl-xL ratio through concurrent mechanisms dependent and independent of its mTOR inhibitory activity.
    Tirado OM, Mateo-Lozano S, Notario V.
    Oncogene; 2005 May 05; 24(20):3348-57. PubMed ID: 15782132
    [Abstract] [Full Text] [Related]

  • 6. Survival signaling by Notch1: mammalian target of rapamycin (mTOR)-dependent inhibition of p53.
    Mungamuri SK, Yang X, Thor AD, Somasundaram K.
    Cancer Res; 2006 May 01; 66(9):4715-24. PubMed ID: 16651424
    [Abstract] [Full Text] [Related]

  • 7. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.
    Cancer Res; 2006 Feb 15; 66(4):2305-13. PubMed ID: 16489035
    [Abstract] [Full Text] [Related]

  • 8. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells.
    Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB, Kondo S.
    Oncogene; 2007 Mar 22; 26(13):1840-51. PubMed ID: 17001313
    [Abstract] [Full Text] [Related]

  • 9. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
    Liu L, Li F, Cardelli JA, Martin KA, Blenis J, Huang S.
    Oncogene; 2006 Nov 09; 25(53):7029-40. PubMed ID: 16715128
    [Abstract] [Full Text] [Related]

  • 10. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K.
    Cancer Res; 2008 Apr 15; 68(8):2934-43. PubMed ID: 18413763
    [Abstract] [Full Text] [Related]

  • 11. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
    Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Tritschler F, Rieger J, Wick W, Weller M, Steinbach JP.
    Brain; 2009 Jun 15; 132(Pt 6):1509-22. PubMed ID: 19416948
    [Abstract] [Full Text] [Related]

  • 12. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB, Miron P, Miron A, Iglehart JD.
    J Surg Res; 2007 Mar 15; 138(1):37-44. PubMed ID: 17109887
    [Abstract] [Full Text] [Related]

  • 13. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 15; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of PKHD1 may cause S-phase entry via mTOR signaling pathway.
    Zheng R, Wang L, Fan J, Zhou Q.
    Cell Biol Int; 2009 Sep 15; 33(9):926-33. PubMed ID: 19524688
    [Abstract] [Full Text] [Related]

  • 15. An expanding role for mTOR in cancer.
    Guertin DA, Sabatini DM.
    Trends Mol Med; 2005 Aug 15; 11(8):353-61. PubMed ID: 16002336
    [Abstract] [Full Text] [Related]

  • 16. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.
    Endocr Relat Cancer; 2008 Mar 15; 15(1):257-66. PubMed ID: 18310292
    [Abstract] [Full Text] [Related]

  • 17. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 18. Acetaldehyde promotes rapamycin-dependent activation of p70(S6K) and glucose uptake despite inhibition of Akt and mTOR in dopaminergic SH-SY5Y human neuroblastoma cells.
    Fang CX, Yang X, Sreejayan N, Ren J.
    Exp Neurol; 2007 Jan 15; 203(1):196-204. PubMed ID: 16962100
    [Abstract] [Full Text] [Related]

  • 19. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F, Papa V, Libra M, Martinelli G, Cocco L, Martelli AM.
    Cancer Res; 2007 May 01; 67(9):4287-94. PubMed ID: 17483341
    [Abstract] [Full Text] [Related]

  • 20. The FRB domain of mTOR: NMR solution structure and inhibitor design.
    Leone M, Crowell KJ, Chen J, Jung D, Chiang GG, Sareth S, Abraham RT, Pellecchia M.
    Biochemistry; 2006 Aug 29; 45(34):10294-302. PubMed ID: 16922504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.